Hologic this week named Stephen MacMillan as president and CEO. MacMillan succeeds Jack Cumming, who held his position for less than five months after returning to Hologic after serving as CEO from 2011 to 2009.
MacMillan is the former president and CEO of Stryker, a global medical device company. Prior to Stryker, he was a senior executive at Pharmacia. He began his career with Procter and Gamble in 1985, and later spent 11 years with Johnson & Johnson in both the US and Europe, eventually becoming president of the joint venture between J&J and Merck.
Hologic also expanded its board of directors by appointing Jonathan Christodoro and Samuel Merksamer, pursuant to a settlement agreement with Carl Icahn. Christodoro is a managing director with Icahn Capital and currently serves on the board of directors at Enzon Pharmaceuticals, Herbalife, and Talisman Energy. Merksamer is also a managing director at Icahn Capital, and serves on the boards of CVR Refining, Ferrous Resources, CVR Energy, American Railcar Industries, Federal-Mogul Corporation, Viskase Companies, PSC Metals, and Talisman Energy.
More details on Hologic's management shakeup can be found here.
Bio-Rad said this week that that it has appointed Robert Malchione to its board of directors effective January 1, 2014.
Malchione has a broad range of experience in corporate strategy and technology development, Bio-Rad said, most notably at Avery Dennison Corporation, where he served as senior vice president of corporate strategy and technology from 2000 to 2011. Prior to that, he served as vice president, director, and partner at Boston Consulting Group.
Malchione is also currently on the board of directors and executive committee for Innovate Pasadena.